CNBX Pharmaceutical (CNBX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Jun 24, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CNBX SEC filings page.
CNBX Pharmaceutical Inc (CNBX) reported $0 in revenue over the twelve months to May 31, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development spending exceeds sales while liabilities dwarf assets, showing a business that has not yet reached scaled operations.
R&D exceeded revenue in both FY2023 and FY2024, reaching149.8% of revenue in FY2024. That spending pattern coincided with revenue falling68.3% , so the reported cost structure still reflects development activity rather than a scaled sales engine.
FY2024 pairs
Operating cash flow was negative in both FY2023 and FY2024, moving from a
Financial Health Signals
We do not publish a peer-relative financial health score for CNBX Pharmaceutical Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
CNBX Pharmaceutical Inc generated $0 in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
CNBX Pharmaceutical Inc earned $0.00 per diluted share (EPS) in Q3 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Not reported for Q3 2026.
Cash & Balance Sheet
CNBX Pharmaceutical Inc held $9K in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
None of these metrics is reported for Q3 2026.
Capital Allocation
None of these metrics is reported for Q3 2026.
CNBX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0 |
| Cost of Revenue | $0n/m | $0n/m | N/A | N/A | $0 | $0-100.0% | N/A | N/A |
| Gross Profit | $0n/m | $0n/m | N/A | N/A | $0 | $0-100.0% | N/A | N/A |
| R&D Expenses | N/A | $0n/m | $0n/m | $0 | $0-100.0% | $0-100.0% | $0-100.0% | N/A |
| SG&A Expenses | N/A | $73K+12.7% | N/A | N/A | $40K-63.1% | $65K-51.6% | $37K-75.3% | N/A |
| Operating Income | N/A | -$73Kn/m | N/A | N/A | -$40Kn/m | -$65Kn/m | -$37Kn/m | -$53K |
| EBITDA | N/A | N/A | N/A | N/A | -$40Kn/m | -$65Kn/m | -$37Kn/m | N/A |
| Interest Expense | N/A | N/A | $46K+1382.9% | N/A | N/A | N/A | $3K-72.7% | N/A |
| Net Income | N/A | -$44Kn/m | N/A | N/A | -$60Kn/m | -$70Kn/m | -$34Kn/m | N/A |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | N/A | $0.00 | $0.00 | $0.00n/m | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | N/A | $0.00 | $0.00 | $0.00n/m | $0.00 |
| Diluted Shares (Avg) | 1.32B | 931M | 733M | N/A | 43M | 32M | 31M+12.1% | N/A |
Not reported in any period shown, so not listed: Income Tax.
CNBX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $13K-31.3% | $15K-70.6% | $11K-50.0% | $18K-41.3% | $19K-76.7% | $51K-69.1% | $22K-94.2% | $31K-93.7% |
| Current Assets | $13K-31.3% | $15K-70.6% | $11K-50.0% | $18K-41.3% | $19K-76.7% | $51K-69.1% | $22K-85.2% | $31K-86.0% |
| Cash & Equivalents | $9K-30.5% | $12K-73.4% | $8K-55.6% | $15K-42.8% | $14K-81.4% | $46K+23.0% | $17K-78.8% | $26K-79.6% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $2.7M+4.6% | $2.5M-2.8% | $2.6M+1.9% | $2.5M+0.1% | $2.6M+0.9% | $2.6M+3.9% | $2.5M+2.2% | $2.5M-0.2% |
| Current Liabilities | $2.7M+4.6% | $2.5M-2.8% | $2.6M+1.9% | $2.5M+0.1% | $2.6M+0.9% | $2.6M+3.9% | $2.5M+2.2% | $2.5M-0.2% |
| Non-Current Liabilities | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Equity | -$2.7Mn/m | -$2.5Mn/m | -$2.6Mn/m | -$2.5Mn/m | -$2.5Mn/m | -$2.6Mn/m | -$2.5Mn/m | -$2.5Mn/m |
| Retained Earnings | -$25.6Mn/m | -$25.4Mn/m | -$25.4Mn/m | -$25.3Mn/m | -$25.1Mn/m | -$25.1Mn/m | -$25.0Mn/m | -$25.0Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
CNBX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$48Kn/m | -$31Kn/m | -$47Kn/m | -$29Kn/m | -$52K-23219.6% | -$52Kn/m | -$39Kn/m | -$48K-335.2% |
| Depreciation & Amortization | N/A | N/A | $0n/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% |
| Stock-Based Compensation | N/A | N/A | $0n/m | N/A | N/A | N/A | $0-100.0% | N/A |
| Investing Cash Flow | N/A | N/A | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0n/m | $0n/m |
| Financing Cash Flow | $45K+125.1% | $35K-56.3% | $40K+33.3% | $30K+2281.6% | $20K+1487.9% | $80Kn/m | $30K+20.0% | $1K-98.1% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
CNBX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Return on Assets | N/A | -296.0%-158.2pp | N/A | N/A | -320.9%-157.6pp | -137.8%+60.8pp | -154.0%-107.9pp | N/A |
| Current Ratio | 0.000.0x | 0.010.0x | 0.000.0x | 0.010.0x | 0.010.0x | 0.020.0x | 0.01-0.1x | 0.01-0.1x |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.00-0.2x | 0.00-0.2x | 0.00 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$2.5M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| CNBX Pharmaceutical Inc CNBX | FY2025 | $0 | N/A | N/A | $161K | — |
| Regen BioPharma Inc RGBP | FY2025 | $237K | -$1.3M | N/A | $406K | — |
| Regenerative Medical Tech RMTG | FY2025 | $5.1M | -$7.8M | N/A | $412K | — |
| Orgenesis Inc ORGS | FY2024 | $1.0M | N/A | N/A | $3.9M | — |
Where CNBX Pharmaceutical Inc Ranks
Frequently Asked Questions
CNBX Pharmaceutical Inc (CNBX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
CNBX Pharmaceutical Inc (CNBX) revenue declined by 100.0% year-over-year, from $130K to $0 in fiscal year 2025.
CNBX Pharmaceutical Inc (CNBX) had $18K in total assets as of fiscal year 2025, including both current and long-term assets.
CNBX Pharmaceutical Inc (CNBX) had a current ratio of 0.01 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
CNBX Pharmaceutical Inc (CNBX) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $161K as of Nov 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
CNBX Pharmaceutical Inc (CNBX) has no price-to-sales ratio at the moment: revenue is not positive (trailing 12 months to May 31, 2026). The market capitalization is $161K as of Nov 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
CNBX Pharmaceutical Inc (CNBX) has negative shareholder equity of -$2.5M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.